IL6R and temporal arteritis: A number of recent case reports, case series, two open-label studies and one phase II, randomized, double-blind, placebo-controlled trial, in addition to GiACTA, a phase III, randomized double-blind, placebo-controlled trial designed to assess the efficacy and safety of tocilizumab in the treatment of GCA, have described the effects of tocilizumab, an IL-6R antagonist, in the treatment of GCA, with improvements reported in clinical symptoms and acute phase reactants, with significant CS-sparing effects [27–35].